Skeletal Plasmacytoma Progression of disease and impact of local treatment

Description: Skeletal Plasmacytoma: Progression of disease and impact of local treatment; an analysis of SEER database Muhammad UMAR Jawad and Sean P Scully Journal of Hematology & Oncology 2009, 2:41 Full text available
Background Previous reports suggest an as yet unidentifiable subset of patients with plasmacytoma will progress to myeloma. The current study sought to establish the risk of developing myeloma and determine the prognostic factors affecting the progression of disease.
Discussion Plasmacytoma consists of two cohorts of patients with different overall survival; those patients that do not progress to systemic disease and those that develop myeloma. Age> 60 years is associated with disease progression. Identifying patients with systemic disease early in the treatment will permit aggressive and novel treatment strategies to be implemented.